Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_assertion type Assertion NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_head.
- NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_assertion description "[Moreover, PRK1 activates AR even in the presence of the AR antagonist cyproterone acetate that is used in the clinical management of prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_provenance.
- NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_assertion evidence source_evidence_literature NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_provenance.
- NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_assertion SIO_000772 12514133 NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_provenance.
- NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_assertion wasDerivedFrom befree-20140225 NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_provenance.
- NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_assertion wasGeneratedBy ECO_0000203 NP850596.RAMfN1SNCDYq7sllr2A4zHr1EyYmphRT45sbi4UF2ZQ_k130_provenance.